感染

订阅

MedSci主页 / 所有栏目 / 感染

默沙东MK-5172/MK-8742治疗HIV/HCV感染疗效强劲

2014-03-07 tomato 生物谷

HIV/HCV感染肝炎艾滋病
关注

默沙东（Merck & Co）3月6日公布了一项正在开展的II期研究（C-WORTHY Study）的新数据。该研究调查了丙型肝炎全口服组合疗法（MK-5172/MK-8742）用于治疗HIV/HCV合并感染的疗效和安全性。研究中，HIV/HCV合并感染患者接受了12周MK-5172/MK-8742治疗后，取得了强劲的HCV抑制，表明该组合疗法用于治疗HIV/HCV合并感染非常有效，同时，

默沙东（Merck & Co）3月6日公布了一项正在开展的II期研究（C-WORTHY Study）的新数据。该研究调查了丙型肝炎全口服组合疗法（MK-5172/MK-8742）用于治疗HIV/HCV合并感染的疗效和安全性。研究中，HIV/HCV合并感染患者接受了12周MK-5172/MK-8742治疗后，取得了强劲的HCV抑制，表明该组合疗法用于治疗HIV/HCV合并感染非常有效，同时，安全性与单纯HCV基因型1感染组中所观察到的一致。

在治疗的12周，HIV/HCV合并感染群体，MK-5172/MK-8742+利巴韦林（RBV）联合治疗组100%（29/29）HCV RNA水平低于25 IU/毫升，MK-5172/MK-8742治疗组为90%（26/29）；HCV单独感染群体，MK-5172/MK-8742治疗组100%（13/13）HCV RNA水平低于25 IU/毫升。相关数据已提交至第21届逆转录病毒和机会性感染大会（CROI 2014）。

MK-5172和MK-8742均属于非常有前途的新一类抗病毒药物。MK-5172是一种实验性HCV NS3/4A蛋白酶抑制剂，MK-8742则是一种实验性HCV NS5A复制复合体抑制剂。此前，FDA于2013年10月授予MK-5172/MK-8742全口服方案突破性疗法认定。

慢性丙型肝炎是默沙东研发的优先重点。目前，该公司正在一个广泛的临床项目中评价MK-5172和MK-8742，包括多种HCV基因型感染初治患者、治疗失败的患者、以及其他重要的HCV亚群，如肝硬化和HCV/HIV合并感染。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1257585, encodeId=2d71125e58554, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sun Mar 09 00:54:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259899, encodeId=9d461259899e3, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Mar 09 00:54:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618953, encodeId=48f11618953a0, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sun Mar 09 00:54:00 CST 2014, time=2014-03-09, status=1, ipAttribution=)]
    2014-03-09 ymljack

    #HCV#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1257585, encodeId=2d71125e58554, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sun Mar 09 00:54:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259899, encodeId=9d461259899e3, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Mar 09 00:54:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618953, encodeId=48f11618953a0, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sun Mar 09 00:54:00 CST 2014, time=2014-03-09, status=1, ipAttribution=)]
    2014-03-09 yese

    #默沙东#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1257585, encodeId=2d71125e58554, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sun Mar 09 00:54:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259899, encodeId=9d461259899e3, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Mar 09 00:54:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618953, encodeId=48f11618953a0, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sun Mar 09 00:54:00 CST 2014, time=2014-03-09, status=1, ipAttribution=)]
    2014-03-09 12498e5fm18(暂无昵称)

    #HCV感染#

    0